To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

February 12, 2019

Today's Rundown

Featured Story

Gilead rocked by phase 3 failure of selonsertib in NASH

A phase 3 trial of Gilead’s NASH prospect selonsertib has bombed. The ASK1 inhibitor was no better than placebo at improving fibrosis, wiping out hopes that selonsertib would spearhead Gilead’s push into a new market.

Top Stories

Bladder cancer readout sees Nektar shares hit

Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help steady the ship.

GV names ex-Agios CEO David Schenkein as general partner

Former Agios Pharmaceuticals CEO David Schenkein has joined the life science investing team at GV. Schenkein will co-lead the life science team at the fund, formerly known as Google Ventures, with Krishna Yeshwant.

[Sponsored] Invert to Convert: Rethinking Patient Recruitment & Enrollment Strategies

90% of clinical trials will meet their enrollment goals if their original timelines are doubled. WCG breaks down the barriers to ramping up and meeting patient enrollment goals. A new approach addresses root causes and accelerates study timelines by 33%.

Once interim, now full-time, Siffert becomes new Abeona chief

João Siffert, M.D., has been given the permanent CEO job at Abeona Therapeutics. A former AveXis director, Siffert was initially brought on as the cell and gene therapy biotech’s head of R&D and its CMO but took over as CEO on a short-term basis after the departure of Carsten Thiel.

Neurogene nets $68.5M to advance gene therapies for rare neurological diseases

Neurogene will push forward multiple gene therapy programs, invest in new technology and build its own viral vector manufacturing site for its therapies.

Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada

The Canada-based units of Boehringer Ingelheim and IBM will work together to employ blockchain recordkeeping technology in clinical trials in what they say will be a first in the country.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Webinar] Biostatistics for Non-Statisticians: Understanding Different Types of Analyses and When to Use Each

If commonly used statistical phrases like two-sample t-test, difference in proportions, or hazard ratio intimidate you, join this webinar for an introduction to statistical analyses in clinical trials.

[Whitepaper] Managing Demand Uncertainty in Biologics Production

When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables.

[Whitepaper] RTSM/IRT: A Roadmap For Developing Systems That Address Current Frustrations

92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper.

[Whitepaper] Six API Challenges That could be Slowing your Development

Download this whitepaper to learn more.

[Whitepaper] Engaging Organized Customers in the Era of the Quadruple Aim

Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim

[Whitepaper] Clinical Validation of a Powerful Immune Assay for Patient Selection

Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens.

[Whitepaper] Host Cell Protein Analysis in Biologic Drug Development

This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis.

[Whitepaper] Integrating clinical research at the Point of Care—A New Operating Model

Clinical trials take too long and cost too much—here's what needs to change.

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence.

[POCKET GUIDE] 3 Steps To Supercharge Your Literature Search

Go from Search to Full-Text Scientific Papers in a Single Click!

[Whitepaper] Achieving launch excellence in the challenging healthcare markets of today

This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets.

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[Whitepaper] Liquid Biopsy Investor Toolkit

With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners.

[Survey] Veeva 2019 Unified Clinical Operations Survey

Share your thoughts on the life sciences industry's progress in improving study execution.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events